These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8087561)
1. The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bridges AJ; Lee A; Schwartz CE; Towle MJ; Littlefield BA Bioorg Med Chem; 1993 Dec; 1(6):403-10. PubMed ID: 8087561 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419 [TBL] [Abstract][Full Text] [Related]
3. Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors. Wilson KJ; Illig CR; Subasinghe N; Hoffman JB; Rudolph MJ; Soll R; Molloy CJ; Bone R; Green D; Randall T; Zhang M; Lewandowski FA; Zhou Z; Sharp C; Maguire D; Grasberger B; DesJarlais RL; Spurlino J Bioorg Med Chem Lett; 2001 Apr; 11(7):915-8. PubMed ID: 11294390 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Rudolph MJ; Illig CR; Subasinghe NL; Wilson KJ; Hoffman JB; Randle T; Green D; Molloy CJ; Soll RM; Lewandowski F; Zhang M; Bone R; Spurlino JC; Deckman IC; Manthey C; Sharp C; Maguire D; Grasberger BL; DesJarlais RL; Zhou Z Bioorg Med Chem Lett; 2002 Feb; 12(3):491-5. PubMed ID: 11814826 [TBL] [Abstract][Full Text] [Related]
6. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Magdolen V; Arroyo de Prada N; Sperl S; Muehlenweg B; Luther T; Wilhelm OG; Magdolen U; Graeff H; Reuning U; Schmitt M Adv Exp Med Biol; 2000; 477():331-41. PubMed ID: 10849761 [No Abstract] [Full Text] [Related]
7. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Xing RH; Mazar A; Henkin J; Rabbani SA Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304 [TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. Subasinghe NL; Illig C; Hoffman J; Rudolph MJ; Wilson KJ; Soll R; Randle T; Green D; Lewandowski F; Zhang M; Bone R; Spurlino J; DesJarlais R; Deckman I; Molloy CJ; Manthey C; Zhou Z; Sharp C; Maguire D; Crysler C; Grasberger B Bioorg Med Chem Lett; 2001 Jun; 11(11):1379-82. PubMed ID: 11378359 [TBL] [Abstract][Full Text] [Related]
12. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator. Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072 [TBL] [Abstract][Full Text] [Related]
13. Novel cyano- and N-isopropylamidino-substituted derivatives of benzo[b]thiophene-2-carboxanilides and benzo[b]thieno[2,3-c]quinolones: synthesis, photochemical synthesis, crystal structure determination, and antitumor evaluation. 2. Jarak I; Kralj M; Suman L; Pavlović G; Dogan J; Piantanida I; Zinić M; Pavelić K; Karminski-Zamola G J Med Chem; 2005 Apr; 48(7):2346-60. PubMed ID: 15801828 [TBL] [Abstract][Full Text] [Related]
14. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Rabbani SA; Harakidas P; Davidson DJ; Henkin J; Mazar AP Int J Cancer; 1995 Dec; 63(6):840-5. PubMed ID: 8847143 [TBL] [Abstract][Full Text] [Related]
15. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models. Bhongade BA; Gadad AK J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Matthews H; Ranson M; Tyndall JD; Kelso MJ Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672 [TBL] [Abstract][Full Text] [Related]